High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia

International Journal of Neuropsychopharmacology

Volumn 7, Issue 4, 2004, Pages 421-430

  Vernaleken, Ingo ^a   Siessmeier, Thomas ^a   Buchholz, Hans Georg ^a   Härtter, Sebastian ^a   Hiemke, Christoph ^a   Stoeter, Peter ^a   Rösch, Frank ^a   Bartenstein, Peter ^a   Gründer, Gerhard ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

18F desmethoxyfallypride; Amisulpride; Atypical antipsychotic; D2 receptor occupancy; Positron emission tomography

Indexed keywords

AMISULPRIDE; DOPAMINE 2 RECEPTOR; O NORFALLYPRIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCULATION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ADULT; ALGORITHMS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CAUDATE NUCLEUS; CEREBRAL CORTEX; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOSTRIATUM; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SCHIZOPHRENIA; SULPIRIDE;

EID: 10644243586     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004353     Document Type: Article

References (38)

1. Barnes TRE (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
2. 123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berlin) 150, 132-140.
3. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995). Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry 166, 68-72.
4. Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS (2003). Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? American Journal of Psychiatry 160, 1413-1420.
5. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ (1990). Amisulpride versus haloperidol in treatment of schizophrenic patients - results of a double-blind study. Pharmacopsychiatry 23, 125-130.
6. Delforge J, Bottlaender M, Loc'h C, Guenther I, Fuseau C, Bendriem B, Syrota A, Mazière B (1999). Quantitation of extrastriatal D2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach. Journal of Cerebral Blood Flow and Metabolism 19, 533-546.
7. 11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. Journal of Cerebral Blood Flow and Metabolism 9, 696-708.
8. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
9. Farde L, Wiesel FA, Hall H, Halldin C, Stone-Elander S, Sedvall G (1987). No D2 receptor increase in PET study of schizophrenia. Archives of General Psychiatry 44, 671-672.
10. Gründer G, Benkert O (2002). Prolactin is not a core dimension of atypicality. Psychopharmacology 762, 93.
11. 18F] desmethoxyfallypride. Journal of Nuclear Medicine 44, 109-116.
12. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology (revised edn). Washington, DC: US Department of Health, Education and Welfare.
13. Hietala J, Syvälahti E, Vuorio K, Någren K, Lehikoinen P, Ruotsalainen U, Räkköläinen V, Lehtinen V, Wegelius U (1994). Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Archives of General Psychiatry 57, 116-123.
14. Kapur S, Remington G (2001). Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry 50, 873-883.
15. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. American Journal of Psychiatry 158, 360-369.
16. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Bulletin 13, 261-276.
17. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158.
18. Le Bricon C, Hulot T, Canal M, Hortan N, Lins RL (1996). Pharmacokinetics of amisulpride and its enantiomers after single and repeated doses in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics (Special Issue), 135-136.
19. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002). Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. American Journal of Psychiatry 159, 180-190.
20. 76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET. Nuclear Medicine and Biology 23, 813-819.
21. Martinot JL, Paillere-Martinot ML, Poirier MF, Dao Castellana MH, Loc'h C, Mazière B (1996). In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berlin) 124, 154-158.
22. Meltzer HY, Shigehiro M, Lee J-C (1989). The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacology Bulletin 25, 390-392.
23. Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J (2001). Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25, 476-488.
24. Nordström A-L, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry 33, 227-235.
25. Olsson H, Farde L (2001). Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - a simulation study based on experimental data. Neuroimage 14, 936-945.
26. Perrault G, Depoortere R, Morel E, Ranger DJ, Scatton B (1997). Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics 280, 73-82.
27. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997). Limbic selectivity of clozapine. Lancet 350, 490-491.
28. Sachse J, Härtter S, Weigmann H, Hiemke C (2003). Automated determination of amisulpride by liquid chromatography with column-switching and spectrophotometric detection. Journal of Chromatography B 784, 405-410.
29. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics 280, 83-97.
30. Schreckenberger M, Hägele S, Siessmeier T, Buchholz H-G, Armbrust-Henrich H, Rösch F, Gründer G, Bartenstein P, Vogt T (In Press). The dopamine D2-receptor ligand 18F-desmethoxyfallypride is an appropriate PET tracer for the differential diagnosis of parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging.
31. Seeman P, Corbett R, Van Tool HH (1997). Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16, 93-110.
32. Simpson GN, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212 (Suppl. 44), 11-19.
33. 123)I]- epidepride single photon emission tomography (SPET) study. British Journal of Psychiatry 177, 408-415.
34. Talairach J, Tournoux P (Eds.) (1988). Co-planar Stereotaxic Atlas of the Human Brain. New York NY: Thieme Medical.
35. 11C]FLB 457. American Journal of Psychiatry 158, 926-930.
36. Wetzel H, Gründer G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schröder J, Rein W, Benkert O (1998). Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology 137, 223-232.
37. Woods RP, Cherry SR, Mazziotta JC (1992). Rapid automated algorithm for aligning and reslicing PET images. Journal of Computer Assisted Tomography 16, 620-633.
38. Xiberas X, Martinot J-L, Mallet L, Artiges E, Canal M, Loc'h C, Mazière B, Paillere-Martinot M-L (2001). In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. Journal of Clinical Psychopharmacology 21, 207-214.